Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 19/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748758 | 1.00 | ACACB (0.82) | ACACB | |
| SCHEMBL12001067 | 0.95 | ACACB (0.76) | ACACB | |
| SCHEMBL256073 | 0.91 | ACACB (1.00) | ACACB | |
| SCHEMBL164441 | 0.86 | ACACB (0.63) | ACACB | |
| SCHEMBL23275246 | 0.86 | ACACB (0.63) | ACACB | |
| SCHEMBL256081 | 0.84 | ACACB (0.61) | ACACB | |
| SCHEMBL8532416 | 0.84 | ACACB (0.82) | ACACB | |
| SCHEMBL11471817 | 0.84 | ACACB (0.63) | ACACB | |
| SCHEMBL256801 | 0.84 | ACACB (0.62) | ACACB | |
| SCHEMBL163430 | 0.84 | ACACB (0.62) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-08 | — | — | US | disclosed |
| EP-3865494-B1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-07-24 | — | — | EP | disclosed |
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| CN-111018918-B | Metal complex, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2022-10-04 | — | — | CN | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-111018918-A | Metal complex, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2020-04-17 | — | — | CN | disclosed |
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| CN-103087105-A | Chiral phosphine ligand and metal catalyst comprising same and application of chiral phosphine ligand and metal catalyst | SHANGHAI INST ORGANIC CHEM | 2013-05-08 | — | — | CN | disclosed |
| CN-103080087-A | Piperidine derivatives and their use for the treatment of metabolic disorders | BOEHRINGER INGELHEIM INT | 2013-05-01 | — | — | CN | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | AP2M1, AP3M1, AP1M1 | ACACB 1337/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | ACACB 2721/4885 |
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | AP2M1, AP3M1, AP1M1 | ACACB 1337/4885 |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885 |
| US-20130165444-A1 | Piperidine Derivatives | PPARD, FABP4, PLIN5 | ACACB 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.